<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:00:02Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10097458" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10097458</identifier>
        <datestamp>2023-04-12</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">8800478</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">1990</journal-id>
              <journal-id journal-id-type="nlm-ta">Brain Behav Immun</journal-id>
              <journal-id journal-id-type="iso-abbrev">Brain Behav Immun</journal-id>
              <journal-title-group>
                <journal-title>Brain, behavior, and immunity</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0889-1591</issn>
              <issn pub-type="epub">1090-2139</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10097458</article-id>
              <article-id pub-id-type="pmcid">PMC10097458</article-id>
              <article-id pub-id-type="pmc-uid">10097458</article-id>
              <article-id pub-id-type="pmid">36058419</article-id>
              <article-id pub-id-type="pmid">36058419</article-id>
              <article-id pub-id-type="doi">10.1016/j.bbi.2022.08.016</article-id>
              <article-id pub-id-type="manuscript">nihpa1888802</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zakiniaeiz</surname>
                    <given-names>Yasmin</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="FN1" ref-type="author-notes">1</xref>
                  <xref rid="CR1" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoye</surname>
                    <given-names>Jocelyn</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                  <xref rid="FN1" ref-type="author-notes">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Petrulli</surname>
                    <given-names>Joseph Ryan</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>LeVasseur</surname>
                    <given-names>Brittany</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stanley</surname>
                    <given-names>Gelsina</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gao</surname>
                    <given-names>Hong</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Najafzadeh</surname>
                    <given-names>Soheila</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ropchan</surname>
                    <given-names>Jim</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nabulsi</surname>
                    <given-names>Nabeel</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Huang</surname>
                    <given-names>Yiyun</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Ming-Kai</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Matuskey</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barron</surname>
                    <given-names>Daniel S.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A4" ref-type="aff">d</xref>
                  <xref rid="A5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kelmendi</surname>
                    <given-names>Benjamin</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fulbright</surname>
                    <given-names>Robert K.</given-names>
                  </name>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hampson</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                  <xref rid="A6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cosgrove</surname>
                    <given-names>Kelly P.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morris</surname>
                    <given-names>Evan D.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A3" ref-type="aff">c</xref>
                  <xref rid="A4" ref-type="aff">d</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>a</label>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA</aff>
              <aff id="A2"><label>b</label>Yale Positron Emission Tomography (PET) Center, Yale School of Medicine, New Haven, CT, USA</aff>
              <aff id="A3"><label>c</label>Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA</aff>
              <aff id="A4"><label>d</label>Department of Psychiatry, Brigham &amp; Women’s Hospital, Boston, MA, USA</aff>
              <aff id="A5"><label>e</label>Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham &amp; Women’s Hospital, Boston, MA, USA</aff>
              <aff id="A6"><label>f</label>Department of Biomedical Engineering, Yale School of Medicine, New Haven, CT, USA</aff>
              <author-notes>
                <fn fn-type="equal" id="FN1">
                  <label>1</label>
                  <p id="P1">These authors contributed equally to this work.</p>
                </fn>
                <corresp id="CR1"><label>*</label>Corresponding author at: 40 Temple Street, Suite 7C, New Haven, CT 06511, USA. <email>yasmin.zakiniaeiz@yale.edu</email> (Y. Zakiniaeiz).</corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>6</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>01</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>12</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <volume>106</volume>
              <fpage>262</fpage>
              <lpage>269</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract id="ABS1">
                <p id="P2">Immune-brain interactions influence the pathophysiology of addiction. Lipopolysaccharide (LPS)-induced systemic inflammation produces effects on reward-related brain regions and the dopamine system. We previously showed that LPS amplifies dopamine elevation induced by methylphenidate (MP), compared to placebo (PBO), in eight healthy controls. However, the effects of LPS on the dopamine system of tobacco smokers have not been explored. The goal of Study 1 was to replicate previous findings in an independent cohort of tobacco smokers. The goal of Study 2 was to combine tobacco smokers with the aforementioned eight healthy controls to examine the effect of LPS on dopamine elevation in a heterogenous sample for power and effect size determination. Eight smokers were each scanned with [<sup>11</sup>C]raclopride positron emission tomography three times—at baseline, after administration of LPS (0.8 ng/kg, intravenously) and MP (40 mg, orally), and after administration of PBO and MP, in a double-blind, randomized order. Dopamine elevation was quantified as change in [<sup>11</sup>C]raclopride binding potential (ΔBP<sub>ND</sub>) from baseline. A repeated-measures ANOVA was conducted to compare LPS and PBO conditions. Smokers and healthy controls were well-matched for demographics, drug dosing, and scanning parameters. In Study 1, MP-induced striatal dopamine elevation was significantly higher following LPS than PBO (<italic toggle="yes">p</italic> = 0.025, 18 ± 2.9 % vs 13 ± 2.7 %) for smokers. In Study 2, MP-induced striatal dopamine elevation was also significantly higher under LPS than under PBO (<italic toggle="yes">p &lt;</italic> 0.001, 18 ± 1.6 % vs 11 ± 1.5 %) in the combined sample. Smoking status did not interact with the effect of condition. This is the first study to translate the phenomenon of amplified dopamine elevation after experimental activation of the immune system to an addicted sample which may have implications for drug reinforcement, seeking, and treatment.</p>
              </abstract>
              <kwd-group>
                <kwd>Lipopolysaccharide</kwd>
                <kwd>Endotoxin</kwd>
                <kwd>Cigarette smoking</kwd>
                <kwd>Dopamine elevation</kwd>
                <kwd>Positron emission tomography</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="S1">
              <label>1.</label>
              <title>Introduction</title>
              <p id="P3">Animal, genetic, postmortem, and imaging data suggest that immune-brain interactions influence the pathophysiology of a broad range of neurologic and psychiatric diseases (<xref rid="R25" ref-type="bibr">Heneka et al., 2015</xref>), including epilepsy (<xref rid="R48" ref-type="bibr">Vezzani and Granata, 2005</xref>), depression (<xref rid="R28" ref-type="bibr">Hodes et al., 2015</xref>; <xref rid="R4" ref-type="bibr">Byrne et al., 2016</xref>), and most relevant, addiction (<xref rid="R8" ref-type="bibr">Crews et al., 2017</xref>; <xref rid="R32" ref-type="bibr">Kelley and Dantzer, 2011</xref>). Studies have demonstrated that drugs and alcohol interact with the neuroimmune system and alter neuroimmune gene expression and signaling (<xref rid="R16" ref-type="bibr">Frank et al., 2011</xref>; <xref rid="R22" ref-type="bibr">Haroon et al., 2012</xref>), which in turn contribute to various reinforcing and addictive properties of addiction including reward, stress, habit formation, and decision-making (<xref rid="R33" ref-type="bibr">Koob and Volkow, 2010</xref>). Further, many immune molecules interact with neurotransmitter systems and play essential roles in modulating synaptic function. For example, inflammatory cytokines, such as interferon-alpha (IFN-α), and their signaling pathways regulate the synthesis, packaging, release, and/or reuptake of several neurotransmitters, including dopamine (<xref rid="R24" ref-type="bibr">Heinisch and Kirby, 2010</xref>; <xref rid="R42" ref-type="bibr">Rostène et al., 2007</xref>). Understanding the mechanisms by which immune activation causes and contributes to addiction could have a broad impact on improving treatment strategies, including identifying impediments to successful treatment and/or identifying new pharmacological targets such as immunomodulating drugs.</p>
              <p id="P4">It is well-established that experimental manipulation of systemic inflammation produces effects on the human brain, especially areas involved in reward (i.e., striatum) (<xref rid="R11" ref-type="bibr">Eisenberger et al., 2010</xref>; <xref rid="R23" ref-type="bibr">Harrison et al., 2015</xref>), and the dopamine system (<xref rid="R10" ref-type="bibr">Dunn, 1992</xref>; <xref rid="R14" ref-type="bibr">Felger et al., 2013</xref>; <xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>; <xref rid="R13" ref-type="bibr">Felger, 2018</xref>). Immune activation can be reliably elicited with lipopolysaccharide (LPS), also called endotoxin, an agonist of the toll-like receptor 4 (TLR4). LPS-induced activation of TLR4 causes systemic inflammation (<xref rid="R20" ref-type="bibr">Hannestad et al., 2012</xref>), activation of microglia (<xref rid="R43" ref-type="bibr">Sandiego et al., 2015</xref>), and changes in neuronal activity (<xref rid="R11" ref-type="bibr">Eisenberger et al., 2010</xref>) and behavior (<xref rid="R54" ref-type="bibr">Woodcock et al., 2021</xref>; <xref rid="R18" ref-type="bibr">Ghahremani et al., 2012</xref>; <xref rid="R41" ref-type="bibr">Robertson et al., 2015</xref>). LPS is also titratable, making it an excellent model that can be given in a precise and repeatable dose (per bodyweight) and delivered consistently across subjects and groups.</p>
              <p id="P5">LPS serves as a biological stressor causing elevated blood pressure, heart rate, cortisol, cytokines, and negative emotion (<xref rid="R20" ref-type="bibr">Hannestad et al., 2012</xref>; <xref rid="R43" ref-type="bibr">Sandiego et al., 2015</xref>; <xref rid="R9" ref-type="bibr">DellaGioia et al., 2013</xref>; <xref rid="R20" ref-type="bibr">Hannestad et al., 2012</xref>; <xref rid="R45" ref-type="bibr">Sorrells and Sapolsky, 2007</xref>). These symptoms caused by LPS are also symptoms experienced due to psychosocial stress and other stressors. Stress is known to increase dopamine transmission in striatum (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>; <xref rid="R30" ref-type="bibr">Imperato et al., 1989</xref>; <xref rid="R52" ref-type="bibr">Wand et al., 2007</xref>) and the likelihood of smoking relapse (<xref rid="R36" ref-type="bibr">McKee et al., 2011</xref>; <xref rid="R44" ref-type="bibr">Sinha, 2001</xref>). An elevated dopamine response in the striatum is linked to important behavioral characteristics of tobacco smoking, such as inhibitory control (<xref rid="R7" ref-type="bibr">Colzato et al., 2007</xref>; <xref rid="R37" ref-type="bibr">Monterosso et al., 2005</xref>) and impulsivity (<xref rid="R2" ref-type="bibr">Bari and Robbins, 2013</xref>). Therefore, LPS is a relevant model for stress-induced smoking relapse. Findings from animal studies have linked LPS to drug reinstatement via three main findings: (1) LPS administration causes elevation of the major stress hormone, corticosterone, in rats, (2) reinstatement of cocaine-seeking occurs following corticosterone administration in rats trained to self-administer cocaine, and (3) corticosterone plus cocaine administration enhances dopamine transmission in ventral striatum compared to cocaine alone using microdialysis. However, much less is known about the molecular events of these effects in humans and specifically, how dopamine mediates the effects of systemic inflammation in tobacco smokers.</p>
              <p id="P6">Previous animal and human studies that examined the effects of inflammation on dopamine did not use the well-established LPS model, but rather, used a pre-treatment with inflammatory cytokines. Rhesus monkeys pre-treated with the cytokine IFN-α, an inflammatory stimulus that increases peripheral cytokines and acts as a biological stressor, showed higher dopamine levels after acute (2 weeks) and lower dopamine levels after chronic (4 weeks) treatment relative to saline, using microdialysis (<xref rid="R14" ref-type="bibr">Felger et al., 2013</xref>). PET imaging of rhesus monkeys treated with 4 weeks of IFN-α showed decreased dopamine release relative to saline in the putamen (<xref rid="R14" ref-type="bibr">Felger et al., 2013</xref>) which can be restored by levodopa (<xref rid="R15" ref-type="bibr">Felger et al., 2015</xref>). In another study, individuals with the hepatitis C virus treated with IFN-α for 4–6 weeks exhibited significantly increased [<sup>18</sup>F]DOPA uptake and decreased [<sup>18</sup>F]DOPA turnover in reward-related regions, including caudate, putamen, and ventral striatum (<xref rid="R5" ref-type="bibr">Capuron et al., 2012</xref>). Functional magnetic resonance imaging (fMRI) of the same subjects under the same protocol showed reduced ventral striatal activation during a hedonic reward task (<xref rid="R5" ref-type="bibr">Capuron et al., 2012</xref>). These findings suggest that dopamine neuro-transmission in reward-related regions such as the striatum is altered by acute and chronic inflammation.</p>
              <p id="P7">Studies that did use the LPS model to examine effects on dopamine were limited to animals, non-molecular methods such as fMRI, and healthy control individuals. In rodents, acute systemic immune activation with LPS produced increases in dopamine release (<xref rid="R10" ref-type="bibr">Dunn, 1992</xref>). fMRI imaging of healthy control subjects showed that ventral striatal activity in response to reward was reduced by an acute dose of LPS (0.8 ng/kg, 2–3 h prior to scanning) (<xref rid="R11" ref-type="bibr">Eisenberger et al., 2010</xref>). Our group was the first to show that LPS, compared to placebo (PBO), amplified methylphenidate (MP)-induced dopamine transmission in striatum in healthy control subjects using PET (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>). These findings suggest that reward activity may be altered following acute LPS-induced immune activation. Based on the ability of LPS to act as a biological stressor and studies showing that stress increases dopamine transmission in striatum (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>; <xref rid="R30" ref-type="bibr">Imperato et al., 1989</xref>; <xref rid="R52" ref-type="bibr">Wand et al., 2007</xref>) and the likelihood of smoking relapse (<xref rid="R36" ref-type="bibr">McKee et al., 2011</xref>; <xref rid="R44" ref-type="bibr">Sinha, 2001</xref>), it is important to translate these findings to tobacco smokers.</p>
              <p id="P8">We previously demonstrated the ability of the LPS model to induce acute systemic inflammation (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>) in healthy control subjects. To determine the wider validity of the LPS model, we sought to replicate and translate this finding in an independent sample of tobacco smokers. In the present study, we examined the effects of LPS administration on MP-induced dopamine elevation in two related studies. In Study 1, we measured the effects of LPS administration on MP-induced dopamine elevation (MP + LPS) relative to PBO (MP + PBO) in tobacco smokers to replicate and translate previous findings from healthy control individuals as part of an ongoing study. In Study 2, after determining that our groups were well-matched on demographics, drug dosing, and scanning parameters, we combined our data in smokers with our previously published data in healthy control individuals (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>), for power and effect size determination in a heterogenous sample. Based on our previous study (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>) and the ability of the LPS model to act as a biological stressor, we hypothesized that LPS administration would amplify MP-induced dopamine elevation in <italic toggle="yes">a priori</italic> (striatum) and exploratory (caudate, putamen, and ventral striatum) regions of interest (ROIs). To our knowledge, this is the first study to examine the phenomenon of amplified dopamine elevation after experimental activation of the immune system in an addicted sample which may have implications for drug reinforcement, seeking, and treatment (<xref rid="R36" ref-type="bibr">McKee et al., 2011</xref>; <xref rid="R44" ref-type="bibr">Sinha, 2001</xref>).</p>
            </sec>
            <sec id="S2">
              <label>2.</label>
              <title>Materials and methods</title>
              <p id="P9">This study was approved by Yale University’s Human Investigation Committee, Radioactive Drug Research Committee, and Radiation Safety Committee. Informed consent was obtained prior to the performance of any study procedures.</p>
              <sec id="S3">
                <label>2.1.</label>
                <title>Study 1:</title>
                <sec id="S4">
                  <label>2.1.1.</label>
                  <title>Subjects</title>
                  <p id="P10">Nine individuals who smoke tobacco (referred to as smokers) (6 female) aged 32 ± 3.6 years (mean ± SE) were studied. Subjects had no history or evidence of significant medical disorders on physical exam and did not meet DSM-5 criteria for current or past psychiatric or substance abuse diagnosis (except nicotine dependence). Smokers smoked 15 ± 2.9 cigarettes per day for 16 ± 4.2 years and had Fagerström Test for Nicotine Dependence (FTND) (<xref rid="R12" ref-type="bibr">Etter et al., 1999</xref>) scores of 5.8 ± 0.8, indicating moderate dependence (<xref rid="T1" ref-type="table">Table 1</xref>). On intake day, smoking status was confirmed by spirometry to measure carbon monoxide (CO) levels &gt; 11 parts per million (ppm) and by urine samples to measure cotinine—the primary metabolite of nicotine—levels &gt; 150 ng/ml (NicAlert cotinine test strips; Nymox Pharmaceutical). On scan day, overnight abstinence was confirmed by CO levels &lt; 10 ppm or ≤ 50 % of their intake level. One male smoker was excluded due to overnight sleep disturbance on the MP + PBO scan day which has been shown to impact dopamine receptor availability (<xref rid="R51" ref-type="bibr">Volkow et al., 2012</xref>) (See <xref rid="SD1" ref-type="supplementary-material">Supplemental Material</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>). Pregnancy and lactation were exclusionary.</p>
                </sec>
                <sec id="S5">
                  <label>2.1.2.</label>
                  <title>Study design</title>
                  <p id="P11">Each subject underwent a structural MRI scan on a Prisma 3T MR scanner (Siemens/CTI, Knoxville, TN, USA) for anatomical localization. Subjects also participated in two PET scan sessions on two separate days (<xref rid="F1" ref-type="fig">Fig. 1</xref>). Each scan session consisted of either a pair of PET scans: a baseline scan and an MP + LPS/PBO scan; or just an MP + LPS/PBO scan. The baseline scan was a 90-min [<sup>11</sup>C]raclopride scan. MP + LPS/ PBO scans consisted of a pre-treatment with either LPS (0.8 ng/kg) or saline PBO administered intravenously at time t = 0 min. After 30 min, subjects received oral MP (40 mg). The MP + LPS/PBO [<sup>11</sup>C]raclopride scan was then performed 60 min after MP administration (90 min after LPS/PBO pre-treatment) for 90 min. The timing of LPS administration was selected to achieve maximal levels of plasma cytokines during PET scanning as previously described (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>; <xref rid="R43" ref-type="bibr">Sandiego et al., 2015</xref>). Subjects returned at least 1-week later for a second scan session that followed the same sequence (LPS/PBO pre-treatment, MP administration, MP + LPS/PBO scan) but with the opposite pre-treatment condition (LPS/PBO). The order of pre-treatment was randomized and double-blinded. Six out of 8 subjects had scan sessions 8 days apart. The average was 22 (SD:28) days apart. Seven out of the eight subjects included received their baseline scan at their first PET scan session. Six out of the eight subjects received MP + PBO for their first post-MP PET scan session. Scan cancellations sometimes alter the original randomization. Order effects were not observed. The dose of MP was determined using previous studies that reported a robust change in raclopride signal (~10–30 % change in dopamine) (<xref rid="R49" ref-type="bibr">Volkow et al., 2001</xref>; <xref rid="R50" ref-type="bibr">Volkow et al., 2002</xref>). The dose of LPS was selected based on previous studies that produced changes in brain activity (<xref rid="R11" ref-type="bibr">Eisenberger et al., 2010</xref>; <xref rid="R20" ref-type="bibr">Hannestad et al., 2012</xref>) and altered the dopamine response to MP (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>).</p>
                </sec>
                <sec id="S6">
                  <label>2.1.3.</label>
                  <title>Imaging data acquisition</title>
                  <p id="P12">Subjects were permitted a light breakfast (without caffeine) prior to scanning. Subjects were not permitted to use anti-inflammatory medications for at least 3 days prior to each scan session. An intravenous catheter was placed for [<sup>11</sup>C]raclopride injection and periodic blood sampling. Blood pressure, heart rate, and temperature were monitored pre-, during, and post-scanning by medical staff to ensure subject well-being.</p>
                  <p id="P13">PET was performed with the High-Resolution Research Tomograph (HRRT; Siemens/CTI; FWHM = 2–3 mm). [<sup>11</sup>C]raclopride was synthesized using methods previously described (<xref rid="R17" ref-type="bibr">Gallezot et al., 2014</xref>). Before each PET scan, a 6-min transmission scan was acquired for attenuation correction. [<sup>11</sup>C]raclopride was administered as a bolus by a computer-controlled pump (Harvard Apparatus, Holliston, MA, USA) and collection of emission data lasted for 90 min. Motion correction was applied using a Polaris Vicra (Northern Digital Inc.) (<xref rid="R6" ref-type="bibr">Carson et al., 2003</xref>) head-mounted device. The system measures and corrects motion, event-by-event.</p>
                  <p id="P14">The administered radiotracer had a mean activity of 19 ± 0.61 mCi and mean mass of 2.3 ± 0.30 μg. Injected activity was compared between conditions (baseline, MP + PBO, MP + LPS) using a single factor analysis of variance (ANOVA). We compared the change in mass between each of the pre-treatment conditions and baseline (MP + PBO – Baseline, MP + LPS – Baseline) using a student’s paired <italic toggle="yes">t</italic>-test. To determine the effect of mass on the D<sub>2</sub> receptor, we used the highest [<sup>11</sup>C]raclopride concentration (in mass units) in the reference region (cerebellum) and the affinity (K<sub>D</sub>) of raclopride for the D<sub>2</sub> receptor (<xref rid="R26" ref-type="bibr">Hietala et al., 1999</xref>), to calculate the largest possible occupancy of the D<sub>2</sub> receptor by unlabeled raclopride (See <xref rid="SD1" ref-type="supplementary-material">Supplemental Material</xref> for the equation).</p>
                </sec>
                <sec id="S7">
                  <label>2.1.4.</label>
                  <title>Image reconstruction</title>
                  <p id="P15">PET emission data were collected in 3D. Two-dimensional sinograms were created with Fourier rebinning. Data were binned into 27 total time frames of 6 × 0.5 min, 3 × 1 min, 2 × 2 min, 16 × 5 min. Data were corrected for attenuation, scatter, dead time, detector sensitivity, and randoms. Images were reconstructed with ordered subset expectation maximization (OSEM) using 2 iterations and 30 subsets (in-house software; IDL) at a voxel size of 1.22 mm × 1.22 mm × 1.23 mm and image volume of 256 × 256 × 207 voxels.</p>
                </sec>
                <sec id="S8">
                  <label>2.1.5.</label>
                  <title>Image harmonization</title>
                  <p id="P16">To harmonize the current smoker dataset (acquired with the HRRT scanner) with the previously collected dataset in healthy controls (acquired with the HR+ scanner), we applied a harmonization method to make the HRRT images resemble HR+ images (as described in (<xref rid="R29" ref-type="bibr">Hoye et al., 2022</xref>). The harmonization method was a two-step process: (1) down-sampling the pixel size of the HRRT images to match the HR+ images, (2) filtering the downsampled images with an isotropic gaussian filter with 4.5 mm FWHM. The harmonized HRRT (hHRRT) images had image dimensions of 152 × 152 × 105 and a voxel size of 2.06 mm × 2.06 mm × 2.43 mm.</p>
                </sec>
                <sec id="S9">
                  <label>2.1.6.</label>
                  <title>Image analysis</title>
                  <p id="P17">Each hHRRT PET image was co-registered to the respective subject’s MR scan and then non-linearly registered to an MR template (MNI2) in a common space (Bioimage Suite (<xref rid="R39" ref-type="bibr">Papademetris et al., 2006</xref>). ROIs were extracted using automated anatomical labeling (<xref rid="R46" ref-type="bibr">Tzourio-Mazoyer et al., 2002</xref>) (AAL) to generate regional time activity curves (for cerebellum, whole striatum, caudate, putamen, and ventral striatum). Time activity curves were fitted with the simplified reference tissue model (<xref rid="R34" ref-type="bibr">Lammertsma and Hume, 1996</xref>) using the cerebellum as a reference region to calculate non-displaceable binding potential (BP<sub>ND</sub>). Change in BP<sub>ND</sub> (ΔBP<sub>ND</sub>) was calculated between baseline and post-MP for both LPS and PBO pre-treatment conditions. Percent change in BP<sub>ND</sub> is an approach that has been used conventionally with several dopamine radiotracers including [<sup>11</sup>C]raclopride, [<sup>18</sup>F]fallypride, [<sup>11</sup>C]PHNO, [<sup>11</sup>C]FLB457 PET, to quantify respective endogenous dopamine (<xref rid="R35" ref-type="bibr">Martinez et al., 2003</xref>; <xref rid="R38" ref-type="bibr">Okita et al., 2016</xref>; <xref rid="R55" ref-type="bibr">Zakiniaeiz et al., 2019</xref>; <xref rid="R53" ref-type="bibr">Whitton et al., 2020</xref>).</p>
                </sec>
                <sec id="S10">
                  <label>2.1.7.</label>
                  <title>Dopamine elevation</title>
                  <p id="P18">To compare differences in MP-induced dopamine elevation, a repeated-measures ANOVA (rmANOVA) featuring condition (MP + LPS vs MP + PBO) as a within-subjects factor was performed on ΔBP<sub>ND</sub> values from our <italic toggle="yes">a priori</italic> ROI, the whole striatum. Each exploratory ROI within the striatum (ventral striatum, caudate, and putamen) was examined with a separate but identical rmANOVA <italic toggle="yes">post-hoc</italic>. The whole striatum was chosen <italic toggle="yes">a priori</italic> based on the previously reported effects of MP-induced dopamine elevation by Petrulli et al. (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>). The subregions were exploratory ROIs and were not corrected for multiple comparisons. Kolmogorov-Smirnov and Shapiro-Wilk tests of normality were conducted to confirm that our ΔBP<sub>ND</sub> values were normally distributed as this is a critical assumption of the rmANOVA model.</p>
                </sec>
                <sec id="S11">
                  <label>2.1.8.</label>
                  <title>Blood and behavior analyses</title>
                  <p id="P19">Samples of venous blood (10 ml) were drawn at 30, 90, 150, 210 min post-MP administration to assess MP concentration and cortisol levels. An additional 10 ml of venous blood samples were drawn at 0, 30, 60, 90, 120, 180, and 210 min post LPS/PBO injection to measure concentrations of the cytokines: tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6) and IL-8. Blood samples were centrifuged for 10 min and the plasma was stored at −80 °C. Plasma samples were assayed for MP (National Medical Services (NMS) Labs, Horsham, PA, USA), and cortisol and cytokines (Yale Center for Clinical Investigations (YCCI) Lab, New Haven, CT, USA).</p>
                  <p id="P20">To confirm that MP plasma levels were the same in both conditions, we compared MP plasma levels within subjects between MP + LPS and MP + PBO conditions at all timepoints using student’s paired <italic toggle="yes">t</italic>-tests. To check that LPS elevated cortisol and cytokine levels relative to PBO, we compared cytokine and cortisol levels at all timepoints between MP + LPS and MP + PBO conditions using student’s paired <italic toggle="yes">t</italic>-tests.</p>
                  <p id="P21">Subjects reported subjective ratings of endotoxin symptoms (headache, muscle pain, shivering, nausea, breathing difficulties, and fatigue) on a 0 to 4 scale at 0, 60, 90, 120, and 180 min post LPS/PBO injection and at the end of the scan day.</p>
                </sec>
              </sec>
              <sec id="S12">
                <label>2.2.</label>
                <title>Study 2:</title>
                <p id="P22">We combined the 8 smokers above with 8 healthy control subjects from the previously published study from our group (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>). We examined this combined sample of 16 subjects to determine power and effect size in a heterogenous sample.</p>
                <sec id="S13">
                  <label>2.2.1.</label>
                  <title>Combining smoker and healthy control groups</title>
                  <p id="P23">Before combining smoker and healthy control groups, a number of data checks were performed (<xref rid="T1" ref-type="table">Table 1</xref>). Differences in age, sex, and scan order were assessed between the two groups using Chi-squared tests. Differences in bodyweight, LPS dose, LPS dose per bodyweight, MP dose per bodyweight, and subjective responses to endotoxin symptoms were assessed using student’s independent-samples <italic toggle="yes">t</italic>-tests. Cytokine and MP plasma levels were also compared between groups using independent-samples student’s <italic toggle="yes">t</italic>-tests at each time point. Cortisol plasma levels were not collected in healthy control subjects and thus, were not compared between groups. Injected activity and difference in injected mass between baseline and MP + LPS and baseline and MP + PBO were compared using student’s independent-samples <italic toggle="yes">t</italic>-tests.</p>
                </sec>
                <sec id="S14">
                  <label>2.2.2.</label>
                  <title>Dopamine elevation</title>
                  <p id="P24">To compare differences in MP-induced dopamine elevation in the combined sample, identical rmANOVAs featuring condition (MP + LPS vs MP + PBO) as a within-subjects factor was performed on whole striatum ΔBP<sub>ND</sub> values, as well as each exploratory ROI (ventral striatum, caudate, and putamen) as described above.</p>
                  <p id="P25">To determine if smoking status affected the ΔBP<sub>ND</sub>, smoking status was added as a between-subjects variable in the rmANOVA model. The rmANOVA was the most appropriate statistical test due to the within-subjects design. Nonetheless, a two-way ANOVA was also used to examine the effect of smoking status. To evaluate whether having only one baseline scan in the Petrulli et al. (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>) study versus two baseline scans would have changed any findings of significance, we arbitrarily chose the first acquired baseline scan to calculate ΔBP<sub>ND</sub> between baseline and MP + LPS/PBO conditions and performed the same rmANOVA.</p>
                </sec>
              </sec>
            </sec>
            <sec id="S15">
              <label>3.</label>
              <title>Results</title>
              <sec id="S16">
                <label>3.1.</label>
                <title>Study 1:</title>
                <sec id="S17">
                  <label>3.1.1.</label>
                  <title>Dopamine elevation</title>
                  <p id="P26">The rmANOVA demonstrated a significant effect of condition (MP + LPS vs MP + PBO; <italic toggle="yes">p</italic> = 0.025, <inline-formula><mml:math id="M1" display="inline"><mml:msubsup><mml:mi>η</mml:mi><mml:mtext>p</mml:mtext><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.54</mml:mn></mml:math></inline-formula>) in the whole striatum whereby dopamine elevation was significantly higher under the MP + LPS (ΔBP<sub>ND</sub> = 18 ± 2.9 %) condition compared to the MP + PBO (ΔBP<sub>ND</sub> = 13 ± 2.7 %) condition (<xref rid="F2" ref-type="fig">Fig. 2</xref>). In exploratory ROIs, there was a significant effect of condition for putamen, ventral striatum, and caudate (<italic toggle="yes">p</italic> = 0.013, <italic toggle="yes">p</italic> = 0.035, <italic toggle="yes">p</italic> = 0.005 respectively; uncorrected).</p>
                </sec>
                <sec id="S18">
                  <label>3.1.2.</label>
                  <title>Blood and behavioral analysis</title>
                  <p id="P27">Mean plasma MP levels were not different at any timepoints between MP + LPS and MP + PBO conditions (p &gt; 0.35). Mean plasma cortisol levels were not different at 0, 30, and 60 min post-LPS injection. For all other timepoints, mean cortisol levels were significantly higher (or trending higher) for the MP + LPS compared to MP + PBO condition (<italic toggle="yes">p &lt;</italic> 0.05 or <italic toggle="yes">p &lt;</italic> 0.08); <xref rid="SD1" ref-type="supplementary-material">Figure S1</xref>). Mean cytokine levels were not different at 0 and 30 min (0.18 &lt; <italic toggle="yes">p</italic> &gt; 0.46) post-LPS injection between MP + LPS and MP + PBO conditions. For all later timepoints (60–210 min), mean cytokine levels were higher (although not always significantly) for the MP + LPS compared to MP + PBO condition (0.72 &lt; p &gt; 0.005; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>). Subjective responses of endotoxin symptoms were nonexistent to mild across conditions and groups (maximum mean rating for any symptom at any timepoint = 0.78).</p>
                </sec>
                <sec id="S19">
                  <label>3.1.3.</label>
                  <title>Injection parameters</title>
                  <p id="P28">Injected activity was not significantly different between conditions (baseline, MP + PBO, MP + LPS) scans (<italic toggle="yes">p</italic> = 0.22). The change in mass between baseline and drug scan was not significantly different between conditions (MP + PBO–Baseline, MP + LPS–Baseline) as characterized by a student’s <italic toggle="yes">t</italic>-test (<italic toggle="yes">p</italic> = 0.78). The largest calculated occupancy of the D<sub>2</sub> receptor by raclopride (mass) was 6.6 %.</p>
                </sec>
              </sec>
              <sec id="S20">
                <label>3.2.</label>
                <title>Study 2:</title>
                <sec id="S21">
                  <label>3.2.1.</label>
                  <title>Combining smoker and healthy control groups</title>
                  <p id="P29">Age, sex, scan order, bodyweight, LPS dose, LPS dose per bodyweight, MP dose per bodyweight, and subjective responses to endotoxin symptoms were not different between groups (p &gt; 0.24; <xref rid="T1" ref-type="table">Table 1</xref>). Cytokines were similarly elevated post-LPS injection in both smoker and healthy control groups (<xref rid="SD1" ref-type="supplementary-material">Table S2</xref>). MP plasma levels were not different between groups at all timepoints (p &gt; 0.33). Injected activity and difference in injected mass between baseline and MP + LPS and baseline and MP + PBO were not different between groups (p &gt; 0.15). These data checks determined that the groups were well-matched and appropriate to be combined.</p>
                </sec>
                <sec id="S22">
                  <label>3.2.2.</label>
                  <title>Dopamine elevation</title>
                  <p id="P30">The rmANOVA demonstrated a significant effect of condition (MP + LPS vs MP + PBO; <italic toggle="yes">p &lt;</italic> 0.001, <inline-formula><mml:math id="M2" display="inline"><mml:msubsup><mml:mi>η</mml:mi><mml:mtext>p</mml:mtext><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.62</mml:mn></mml:math></inline-formula>) in the whole striatum whereby dopamine elevation was significantly higher under the MP + LPS (ΔBP<sub>ND</sub> = 18 ± 1.6 %) condition compared to the MP + PBO (ΔBP<sub>ND</sub> = 11 ± 1.5 %) condition (<xref rid="F3" ref-type="fig">Fig. 3</xref>) in the combined sample. In exploratory ROIs, there was a significant effect of condition for putamen (<italic toggle="yes">p &lt;</italic> 0.001) and caudate (<italic toggle="yes">p</italic> = 0.003), but not ventral striatum (<italic toggle="yes">p</italic> = 0.111), uncorrected.</p>
                  <p id="P31">The rmANOVA with smoking status as a between-subjects variable demonstrated that the main effect of smoking status was not significant for whole striatum (<italic toggle="yes">p</italic> = 0.35) or for exploratory ROIs (<italic toggle="yes">p &gt;</italic> 0.27) and that smoking status did not interact with the effect of condition for the whole striatum (<italic toggle="yes">p</italic> = 0.35) or for exploratory ROIs (<italic toggle="yes">p &gt;</italic> 0.21). Using a two-way ANOVA does not change the significance of any reported findings (<italic toggle="yes">p</italic>’s &gt; 0.32). Based on power analyses (<xref rid="SD1" ref-type="supplementary-material">Supplemental Material</xref>), our study is sufficiently powered to detect condition and group differences of interest, despite the small sample size. Using the first acquired baseline scan for the healthy control subjects (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>) did not change any findings of significance compared to using both baseline scans.</p>
                </sec>
              </sec>
            </sec>
            <sec id="S23">
              <label>4.</label>
              <title>Discussion</title>
              <p id="P32">This is the first double-blind, randomized, placebo-controlled, cross-over study to examine MP + LPS-induced dopamine elevation in tobacco smokers. LPS administration produced an acute systemic inflammatory response and biological stress as evidenced by elevated cytokine and cortisol levels under the LPS condition compared to PBO, consistent with prior studies examining healthy control subjects from our group and others (<xref rid="R11" ref-type="bibr">Eisenberger et al., 2010</xref>; <xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>; <xref rid="R21" ref-type="bibr">Hannestad et al., 2012</xref>; <xref rid="R9" ref-type="bibr">DellaGioia et al., 2013</xref>; <xref rid="R19" ref-type="bibr">Hannestad et al., 2011</xref>; <xref rid="R1" ref-type="bibr">Bach et al., 2016</xref>2016). Subjective ratings of LPS symptoms were mild, and consistent with subjective ratings in our previous MP + LPS study (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>). In Study 1, as hypothesized, MP-induced dopamine elevation was amplified by LPS in the striatum, replicating and translating our previous finding in 8 healthy control individuals (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>) to tobacco smokers. In Study 2, we combined 8 smokers from the present study with the 8 healthy control individuals from the aforementioned study from our group. Groups were well-matched on demographics, injection parameters, and subjective responses to LPS. Smoking status did not interact with the effect of condition. In the combined cohort of 16 subjects, MP-induced dopamine elevation in the striatum was amplified in the presence of LPS, suggesting that acute systemic inflammation by LPS magnifies the dopamine response in both smokers and healthy controls.</p>
              <p id="P33">Building on our prior work in healthy control individuals from our group (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>), we replicated and translated our finding that dopamine elevation is amplified by an acute dose of LPS to an independent cohort of tobacco smokers. Our central finding links LPS-induced neuroimmune activation, a type of biological stress, to hyper-responsivity of the dopamine system in tobacco smokers. To our knowledge, this was the first study to assess the impact of an acute laboratory-based stressor on the reward system of tobacco smokers. The application of our LPS-based human laboratory model was successful in eliciting an acute systemic inflammatory stress response in tobacco smokers and may be applicable to other addicted samples, generally.</p>
              <p id="P34">Although not studied here, we believe the distinction between chronic and acute inflammation is important. Petrulli et al. (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>) found that an acute dose of LPS (one dose 1.5 h prior to scanning) in human subjects resulted in amplified striatal dopamine elevation relative to placebo (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>). Felger et al. (<xref rid="R14" ref-type="bibr">Felger et al., 2013</xref>) found that chronic (4 week) administration of inflammatory cytokines in rhesus monkeys resulted in lower striatal dopamine release relative to placebo. However, that same study also showed that short-term (2 weeks) administration resulted in increased striatal dopamine release relative to placebo (<xref rid="R14" ref-type="bibr">Felger et al., 2013</xref>). In rodents, acute systemic immune activation with LPS produced increases in dopamine (<xref rid="R10" ref-type="bibr">Dunn, 1992</xref>). The exact biological distinction between acute and chronic inflammation is still unknown. It is possible that acute doses of inflammation may cause turnover of neuroendocrine peptides resulting in short-term higher dopamine release prior to long-term lower dopamine release (<xref rid="R13" ref-type="bibr">Felger, 2018</xref>).</p>
              <p id="P35">Although our findings were similar between smokers and healthy controls, our study identified subtleties that might have implications for smoking reinforcement, consequences of drug use, and treatment. We observed a difference in the ventral striatum between smokers and healthy control individuals. Study 1 revealed that relative to PBO, LPS amplified MP-induced dopamine elevation in tobacco smokers in ventral striatum. Our previously published findings in healthy control individuals (<xref rid="R40" ref-type="bibr">Petrulli et al., 2017</xref>) did not detect differences between LPS and PBO conditions in the ventral striatum. Ventral striatum is a critical component of the reward-related circuitry and dopamine release in ventral striatum underlies the reinforcing properties of tobacco smoking. It is possible that LPS amplification of the dopamine signal in ventral striatum may explain why tobacco smokers continue to smoke or perhaps this may be a consequence of chronic smoking that may hinder responses to treatment. Because biological stress, such as immune activation, increases the likelihood of smoking relapse (<xref rid="R36" ref-type="bibr">McKee et al., 2011</xref>; <xref rid="R44" ref-type="bibr">Sinha, 2001</xref>), this finding suggests that ventral striatum may be an understudied leading edge in identifying how systemic inflammation and biological stress affect tobacco smokers differentially.</p>
              <p id="P36">The present study was designed to assess the effects of systemic inflammation on dopamine in tobacco smokers and was not designed to directly assess neuroinflammation in smokers. The effects of smoking on neuroinflammation are not fully understood and may depend on abstinence time. <xref rid="R3" ref-type="bibr">Brody et al. (2017)</xref> showed that smokers have lower TSPO receptor availability than healthy controls as measured with [<sup>11</sup>C] DAA1106. A similar TSPO receptor availability study by <xref rid="R27" ref-type="bibr">Hillmer et al. (2020)</xref> found no difference in TSPO levels between smokers and healthy controls. In Brody et al. smokers were scanned in a satiated state and in Hillmer et al. smokers were abstinent for 2–14 h. Future studies should assess TSPO receptor availability in smokers pre-treated with LPS compared to placebo and the effect of smoking abstinence.</p>
              <p id="P37">This study had some potential limitations that were addressed as well as several strengths. First, the comparison of smokers in Study 1 and healthy controls in Study 2 was limited by the use of two different PET scanners. However, we went to great lengths to harmonize the image resolution by scanning an independent set of subjects on both scanners (<xref rid="R29" ref-type="bibr">Hoye et al., 2022</xref>). This was essential to produce an appropriate comparison to our previous data. Other groups have taken similar steps to harmonize data acquired with different PET scanners (<xref rid="R31" ref-type="bibr">Joshi et al., 2009</xref>; <xref rid="R47" ref-type="bibr">van Velden et al., 2015</xref>). Another potential limitation was our small sample size of 8 smoking subjects. However, large effect sizes, high power, and our finding in the combined sample of 16 healthy control subjects gives us confidence. We demonstrated that our LPS model is capable of amplifying the dopamine response and serving as an immune activator and biological stressor in smoker and healthy control samples in a laboratory setting. It will be important for future work to examine how the magnitude of dopamine release might be related to smoking-related behavioral variables. Future studies should consider exploring the effect of LPS on other neurotransmitter systems (beyond dopamine). Future studies should adopt this LPS model to examine the interactions of the immune and dopamine systems in other neuropsychiatric populations. Future work should also study groups that have suffered chronic stress or immune activation through natural events and causes.</p>
            </sec>
            <sec id="S24">
              <label>5.</label>
              <title>Conclusions</title>
              <p id="P38">MP-induced dopamine elevation in the striatum was amplified by the administration of LPS to tobacco smokers and in the combined sample of smokers and healthy controls. The application of our LPS-based human laboratory model was successful in eliciting an acute systemic inflammatory response translating our previous findings in an independent sample of addicted individuals. The effect of inflammation on dopamine release could have important implications in drug reinforcement.</p>
            </sec>
            <sec sec-type="supplementary-material" id="SM1">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <label>Supplementary Material</label>
                <media xlink:href="NIHMS1888802-supplement-Supplementary_Material.docx" id="d64e963" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S26">
              <title>Acknowledgements</title>
              <p id="P40">The authors would like to thank Jon-Michael Anderson for his recruitment efforts. We thank the Yale PET Center staff for imaging and chemistry support.</p>
              <sec id="S27">
                <title>Funding and disclosures</title>
                <p id="P41">The study was supported by the National Institutes of Health R01DA045465 (EDM) and R21 AG043702-01 (EDM). YZ was supported by the SCORE Career Enhancement Core Program (U54AA027989). The authors declare no conflict of interest.</p>
                <p id="P42">This publication was made possible by CTSA Grant No KL2 TR001862 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.</p>
              </sec>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement" id="FN2">
                <p id="P43">Declaration of Competing Interest</p>
                <p id="P44">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
              </fn>
              <fn id="FN3">
                <p id="P45">Appendix A. Supplementary data</p>
                <p id="P46">Supplementary data to this article can be found online at <ext-link xlink:href="10.1016/j.bbi.2022.08.016" ext-link-type="doi">https://doi.org/10.1016/j.bbi.2022.08.016</ext-link>.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability" id="S25">
              <title>Data availability</title>
              <p id="P39">The data used in this study are not openly available at this time because the study is ongoing. Software and code are available upon request.</p>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <mixed-citation publication-type="journal"><name><surname>Bach</surname><given-names>E</given-names></name>, <name><surname>Møller</surname><given-names>AB</given-names></name>, <name><surname>Jørgensen</surname><given-names>JOL</given-names></name>, <name><surname>Vendelbo</surname><given-names>MH</given-names></name>, <name><surname>Jessen</surname><given-names>N</given-names></name>, <name><surname>Pedersen</surname><given-names>SB</given-names></name>, <name><surname>Nielsen</surname><given-names>TS</given-names></name>, <name><surname>Møller</surname><given-names>N</given-names></name>, <year>2016</year>. <article-title>Stress hormone release is a key component of the metabolic response to lipopolysaccharide: studies in hypopituitary and healthy subjects</article-title>. <source>Eur. J. Endocrinol</source><volume>175</volume> (<issue>5</issue>), <fpage>455</fpage>–<lpage>465</lpage>.<pub-id pub-id-type="pmid">27562403</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <mixed-citation publication-type="journal"><name><surname>Bari</surname><given-names>A</given-names></name>, <name><surname>Robbins</surname><given-names>TW</given-names></name>, <year>2013</year>. <article-title>Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD</article-title>. <source>Psychopharmacology</source><volume>230</volume> (<issue>1</issue>), <fpage>89</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-013-3141-6</pub-id>.<pub-id pub-id-type="pmid">23681165</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <mixed-citation publication-type="journal"><name><surname>Brody</surname><given-names>AL</given-names></name>, <name><surname>Hubert</surname><given-names>R</given-names></name>, <name><surname>Enoki</surname><given-names>R</given-names></name>, <name><surname>Garcia</surname><given-names>LY</given-names></name>, <name><surname>Mamoun</surname><given-names>MS</given-names></name>, <name><surname>Okita</surname><given-names>K</given-names></name>, <name><surname>London</surname><given-names>ED</given-names></name>, <name><surname>Nurmi</surname><given-names>EL</given-names></name>, <name><surname>Seaman</surname><given-names>LC</given-names></name>, <name><surname>Mandelkern</surname><given-names>MA</given-names></name>, <year>2017</year>. <article-title>Effect of cigarette smoking on a marker for neuroinflammation: A [(11)C]DAA1106 positron emission tomography study</article-title>. <source>Neuropsychopharmacology</source><volume>42</volume> (<issue>8</issue>), <fpage>1630</fpage>–<lpage>1639</lpage>.<pub-id pub-id-type="pmid">28262740</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <mixed-citation publication-type="journal"><name><surname>Byrne</surname><given-names>ML</given-names></name>, <name><surname>Whittle</surname><given-names>S</given-names></name>, <name><surname>Allen</surname><given-names>NB</given-names></name>, <year>2016</year>. <article-title>The role of brain structure and function in the association between inflammation and depressive symptoms: a systematic review</article-title>. <source>Psychosom. Med</source><volume>78</volume> (<issue>4</issue>), <fpage>389</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="pmid">26910795</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <mixed-citation publication-type="journal"><name><surname>Capuron</surname><given-names>L</given-names></name>, <name><surname>Pagnoni</surname><given-names>G</given-names></name>, <name><surname>Drake</surname><given-names>DF</given-names></name>, <name><surname>Woolwine</surname><given-names>BJ</given-names></name>, <name><surname>Spivey</surname><given-names>JR</given-names></name>, <name><surname>Crowe</surname><given-names>RJ</given-names></name>, <name><surname>Votaw</surname><given-names>JR</given-names></name>, <name><surname>Goodman</surname><given-names>MM</given-names></name>, <name><surname>Miller</surname><given-names>AH</given-names></name>, <year>2012</year>. <article-title>Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration</article-title>. <source>Arch. Gen. Psychiatry</source><volume>69</volume> (<issue>10</issue>), <fpage>1044</fpage>.<pub-id pub-id-type="pmid">23026954</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <mixed-citation publication-type="confproc"><name><surname>Carson</surname><given-names>RE</given-names></name>, <name><surname>Barker</surname><given-names>W</given-names></name>, <name><surname>Liow</surname><given-names>J</given-names></name>, <name><surname>Johnson</surname><given-names>C</given-names></name>, <year>2003</year>. <article-title>Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT</article-title>. <conf-name>In: 2003 IEEE Nuclear Science Symposium Conference Record (IEEE Cat No03CH37515)</conf-name>, pp. <fpage>3281</fpage>–<lpage>3285</lpage>.</mixed-citation>
              </ref>
              <ref id="R7">
                <mixed-citation publication-type="journal"><name><surname>Colzato</surname><given-names>LS</given-names></name>, <name><surname>van den Wildenberg</surname><given-names>WPM</given-names></name>, <name><surname>Hommel</surname><given-names>B</given-names></name>, <name><surname>García</surname><given-names>AV</given-names></name>, <year>2007</year>. <article-title>Impaired inhibitory control in recreational cocaine users</article-title>. <source>PLoS ONE</source><volume>2</volume> (<issue>11</issue>). <pub-id pub-id-type="doi">10.1371/journal.pone.0001143</pub-id>.</mixed-citation>
              </ref>
              <ref id="R8">
                <mixed-citation publication-type="journal"><name><surname>Crews</surname><given-names>FT</given-names></name>, <name><surname>Lawrimore</surname><given-names>CJ</given-names></name>, <name><surname>Walter</surname><given-names>TJ</given-names></name>, <name><surname>Coleman</surname><given-names>LG</given-names><suffix>Jr.</suffix></name>, <year>2017</year>. <article-title>The role of neuroimmune signaling in alcoholism</article-title>. <source>Neuropharmacology</source><volume>122</volume>, <fpage>56</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.01.031</pub-id>.<pub-id pub-id-type="pmid">28159648</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <mixed-citation publication-type="journal"><name><surname>DellaGioia</surname><given-names>N</given-names></name>, <name><surname>Devine</surname><given-names>L</given-names></name>, <name><surname>Pittman</surname><given-names>B</given-names></name>, <name><surname>Hannestad</surname><given-names>J</given-names></name>, <year>2013</year>. <article-title>Bupropion pre-treatment of endotoxin-induced depressive symptoms</article-title>. <source>Brain Behav. Immun</source><volume>31</volume>, <fpage>197</fpage>–<lpage>204</lpage>.<pub-id pub-id-type="pmid">23064079</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <mixed-citation publication-type="journal"><name><surname>Dunn</surname><given-names>AJ</given-names></name>, <year>1992</year>. <article-title>Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1</article-title>. <source>J. Pharmacol. Exp. Ther</source><volume>261</volume> (<issue>3</issue>), <fpage>964</fpage>–<lpage>969</lpage>.<pub-id pub-id-type="pmid">1602402</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <mixed-citation publication-type="journal"><name><surname>Eisenberger</surname><given-names>NI</given-names></name>, <name><surname>Berkman</surname><given-names>ET</given-names></name>, <name><surname>Inagaki</surname><given-names>TK</given-names></name>, <name><surname>Rameson</surname><given-names>LT</given-names></name>, <name><surname>Mashal</surname><given-names>NM</given-names></name>, <name><surname>Irwin</surname><given-names>MR</given-names></name>, <year>2010</year>. <article-title>Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward</article-title>. <source>Biol. Psychiatry</source><volume>68</volume> (<issue>8</issue>), <fpage>748</fpage>–<lpage>754</lpage>.<pub-id pub-id-type="pmid">20719303</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <mixed-citation publication-type="journal"><name><surname>Etter</surname><given-names>J-F</given-names></name>, <name><surname>Duc</surname><given-names>TV</given-names></name>, <name><surname>Perneger</surname><given-names>TV</given-names></name>, <year>1999</year>. <article-title>Validity of the Fagerstrom test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers</article-title>. <source>Addiction</source>. <volume>94</volume> (<issue>2</issue>), <fpage>269</fpage>–<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1046/j.1360-0443.1999.94226910.x</pub-id>.<pub-id pub-id-type="pmid">10396794</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <mixed-citation publication-type="journal"><name><surname>Felger</surname><given-names>JC</given-names></name>, <year>2018</year>. <article-title>Imaging the role of inflammation in mood and anxiety-related disorders</article-title>. <source>Curr Neuropharmacol</source>. <volume>16</volume> (<issue>5</issue>), <fpage>533</fpage>–<lpage>558</lpage>. <pub-id pub-id-type="doi">10.2174/1570159x15666171123201142</pub-id>.<pub-id pub-id-type="pmid">29173175</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <mixed-citation publication-type="journal"><name><surname>Felger</surname><given-names>JC</given-names></name>, <name><surname>Mun</surname><given-names>J</given-names></name>, <name><surname>Kimmel</surname><given-names>HL</given-names></name>, <name><surname>Nye</surname><given-names>JA</given-names></name>, <name><surname>Drake</surname><given-names>DF</given-names></name>, <name><surname>Hernandez</surname><given-names>CR</given-names></name>, <name><surname>Freeman</surname><given-names>AA</given-names></name>, <name><surname>Rye</surname><given-names>DB</given-names></name>, <name><surname>Goodman</surname><given-names>MM</given-names></name>, <name><surname>Howell</surname><given-names>LL</given-names></name>, <name><surname>Miller</surname><given-names>AH</given-names></name>, <year>2013</year>. <article-title>Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates</article-title>. <source>Neuropsychopharmacology</source>. <volume>38</volume> (<issue>11</issue>), <fpage>2179</fpage>–<lpage>2187</lpage>.<pub-id pub-id-type="pmid">23657438</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <mixed-citation publication-type="journal"><name><surname>Felger</surname><given-names>JC</given-names></name>, <name><surname>Hernandez</surname><given-names>CR</given-names></name>, <name><surname>Miller</surname><given-names>AH</given-names></name>, <year>2015</year>. <article-title>Levodopa reverses cytokine-induced reductions in striatal dopamine release</article-title>. <source>Int J Neuropsychopharmacol</source>. <volume>18</volume> (<issue>4</issue>).</mixed-citation>
              </ref>
              <ref id="R16">
                <mixed-citation publication-type="journal"><name><surname>Frank</surname><given-names>MG</given-names></name>, <name><surname>Watkins</surname><given-names>LR</given-names></name>, <name><surname>Maier</surname><given-names>SF</given-names></name>, <year>2011</year>. <article-title>Stress- and glucocorticoid-induced priming of neuroinflammatory responses: potential mechanisms of stress-induced vulnerability to drugs of abuse</article-title>. <source>Brain Behav. Immun</source><volume>25</volume> (<issue>Suppl 1</issue>), <fpage>S21</fpage>–<lpage>S28</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2011.01.005</pub-id>.<pub-id pub-id-type="pmid">21256955</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <mixed-citation publication-type="journal"><name><surname>Gallezot</surname><given-names>J-D</given-names></name>, <name><surname>Kloczynski</surname><given-names>T</given-names></name>, <name><surname>Weinzimmer</surname><given-names>D</given-names></name>, <name><surname>Labaree</surname><given-names>D</given-names></name>, <name><surname>Zheng</surname><given-names>M-Q</given-names></name>, <name><surname>Lim</surname><given-names>K</given-names></name>, <name><surname>Rabiner</surname><given-names>EA</given-names></name>, <name><surname>Ridler</surname><given-names>K</given-names></name>, <name><surname>Pittman</surname><given-names>B</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Carson</surname><given-names>RE</given-names></name>, <name><surname>Morris</surname><given-names>ED</given-names></name>, <name><surname>Cosgrove</surname><given-names>KP</given-names></name>, <year>2014</year>. <article-title>Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [(11)C]PHNO vs [(11)C]raclopride PET</article-title>. <source>NPP</source>. <volume>39</volume> (<issue>4</issue>), <fpage>866</fpage>–<lpage>874</lpage>.</mixed-citation>
              </ref>
              <ref id="R18">
                <mixed-citation publication-type="journal"><name><surname>Ghahremani</surname><given-names>DG</given-names></name>, <name><surname>Lee</surname><given-names>B</given-names></name>, <name><surname>Robertson</surname><given-names>CL</given-names></name>, <name><surname>Tabibnia</surname><given-names>G</given-names></name>, <name><surname>Morgan</surname><given-names>AT</given-names></name>, <name><surname>De Shetler</surname><given-names>N</given-names></name>, <etal/>, <year>2012</year>. <article-title>Striatal dopamine D<sub>2</sub>/D<sub>3</sub> receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans</article-title>. <source>J. Neurosci</source><volume>32</volume> (<issue>21</issue>), <fpage>7316</fpage>–<lpage>7324</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4284-11.2012</pub-id>.<pub-id pub-id-type="pmid">22623677</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <mixed-citation publication-type="journal"><name><surname>Hannestad</surname><given-names>J</given-names></name>, <name><surname>DellaGioia</surname><given-names>N</given-names></name>, <name><surname>Ortiz</surname><given-names>N</given-names></name>, <name><surname>Pittman</surname><given-names>B</given-names></name>, <name><surname>Bhagwagar</surname><given-names>Z</given-names></name>, <year>2011</year>. <article-title>Citalopram reduces endotoxin-induced fatigue</article-title>. <source>Brain Behav Immun</source>. <volume>25</volume> (<issue>2</issue>), <fpage>256</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2010.10.013</pub-id>.<pub-id pub-id-type="pmid">20955776</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <mixed-citation publication-type="journal"><name><surname>Hannestad</surname><given-names>J</given-names></name>, <name><surname>Gallezot</surname><given-names>J-D</given-names></name>, <name><surname>Schafbauer</surname><given-names>T</given-names></name>, <name><surname>Lim</surname><given-names>K</given-names></name>, <name><surname>Kloczynski</surname><given-names>T</given-names></name>, <name><surname>Morris</surname><given-names>ED</given-names></name>, <name><surname>Carson</surname><given-names>RE</given-names></name>, <name><surname>Ding</surname><given-names>Y-S</given-names></name>, <name><surname>Cosgrove</surname><given-names>KP</given-names></name>, <year>2012</year>. <article-title>Endotoxin-induced systemic inflammation activates microglia: [<sup>11</sup>C]PBR28 positron emission tomography in nonhuman primates</article-title>. <source>Neuroimage</source>. <volume>63</volume> (<issue>1</issue>), <fpage>232</fpage>–<lpage>239</lpage>.<pub-id pub-id-type="pmid">22776451</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <mixed-citation publication-type="journal"><name><surname>Hannestad</surname><given-names>J</given-names></name>, <name><surname>Subramanyam</surname><given-names>K</given-names></name>, <name><surname>DellaGioia</surname><given-names>N</given-names></name>, <name><surname>Planeta-Wilson</surname><given-names>B</given-names></name>, <name><surname>Weinzimmer</surname><given-names>D</given-names></name>, <name><surname>Pittman</surname><given-names>B</given-names></name>, <name><surname>Carson</surname><given-names>RE</given-names></name>, <year>2012</year>. <article-title>Glucose metabolism in the insula and cingulate is affected by systemic inflammation in humans</article-title>. <source>J. Nucl. Med</source><volume>53</volume> (<issue>4</issue>), <fpage>601</fpage>–<lpage>607</lpage>.<pub-id pub-id-type="pmid">22414635</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <mixed-citation publication-type="journal"><name><surname>Haroon</surname><given-names>E</given-names></name>, <name><surname>Raison</surname><given-names>CL</given-names></name>, <name><surname>Miller</surname><given-names>AH</given-names></name>, <year>2012</year>. <article-title>Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior</article-title>. <source>Neuropsychopharmacology</source>. <volume>37</volume> (<issue>1</issue>), <fpage>137</fpage>–<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2011.205</pub-id>.<pub-id pub-id-type="pmid">21918508</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <mixed-citation publication-type="journal"><name><surname>Harrison</surname><given-names>NA</given-names></name>, <name><surname>Cercignani</surname><given-names>M</given-names></name>, <name><surname>Voon</surname><given-names>V</given-names></name>, <name><surname>Critchley</surname><given-names>HD</given-names></name>, <year>2015</year>. <article-title>Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants</article-title>. <source>Neuropsychopharmacology</source>. <volume>40</volume> (<issue>4</issue>), <fpage>831</fpage>–<lpage>838</lpage>.<pub-id pub-id-type="pmid">25154706</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <mixed-citation publication-type="journal"><name><surname>Heinisch</surname><given-names>S</given-names></name>, <name><surname>Kirby</surname><given-names>LG</given-names></name>, <year>2010</year>. <article-title>SDF-1alpha/CXCL12 enhances GABA and glutamate synaptic activity at serotonin neurons in the rat dorsal raphe nucleus</article-title>. <source>Neuropharmacology</source><volume>58</volume> (<issue>2</issue>), <fpage>501</fpage>–<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2009.08.022</pub-id>.<pub-id pub-id-type="pmid">19755127</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <mixed-citation publication-type="journal"><name><surname>Heneka</surname><given-names>MT</given-names></name>, <name><surname>Carson</surname><given-names>MJ</given-names></name>, <name><surname>Khoury</surname><given-names>JE</given-names></name>, <name><surname>Landreth</surname><given-names>GE</given-names></name>, <name><surname>Brosseron</surname><given-names>F</given-names></name>, <name><surname>Feinstein</surname><given-names>DL</given-names></name>, <name><surname>Jacobs</surname><given-names>AH</given-names></name>, <name><surname>Wyss-Coray</surname><given-names>T</given-names></name>, <name><surname>Vitorica</surname><given-names>J</given-names></name>, <name><surname>Ransohoff</surname><given-names>RM</given-names></name>, <name><surname>Herrup</surname><given-names>K</given-names></name>, <name><surname>Frautschy</surname><given-names>SA</given-names></name>, <name><surname>Finsen</surname><given-names>B</given-names></name>, <name><surname>Brown</surname><given-names>GC</given-names></name>, <name><surname>Verkhratsky</surname><given-names>A</given-names></name>, <name><surname>Yamanaka</surname><given-names>K</given-names></name>, <name><surname>Koistinaho</surname><given-names>J</given-names></name>, <name><surname>Latz</surname><given-names>E</given-names></name>, <name><surname>Halle</surname><given-names>A</given-names></name>, <name><surname>Petzold</surname><given-names>GC</given-names></name>, <name><surname>Town</surname><given-names>T</given-names></name>, <name><surname>Morgan</surname><given-names>D</given-names></name>, <name><surname>Shinohara</surname><given-names>ML</given-names></name>, <name><surname>Perry</surname><given-names>VH</given-names></name>, <name><surname>Holmes</surname><given-names>C</given-names></name>, <name><surname>Bazan</surname><given-names>NG</given-names></name>, <name><surname>Brooks</surname><given-names>DJ</given-names></name>, <name><surname>Hunot</surname><given-names>S</given-names></name>, <name><surname>Joseph</surname><given-names>B</given-names></name>, <name><surname>Deigendesch</surname><given-names>N</given-names></name>, <name><surname>Garaschuk</surname><given-names>O</given-names></name>, <name><surname>Boddeke</surname><given-names>E</given-names></name>, <name><surname>Dinarello</surname><given-names>CA</given-names></name>, <name><surname>Breitner</surname><given-names>JC</given-names></name>, <name><surname>Cole</surname><given-names>GM</given-names></name>, <name><surname>Golenbock</surname><given-names>DT</given-names></name>, <name><surname>Kummer</surname><given-names>MP</given-names></name>, <year>2015</year>. <article-title>Neuroinflammation in Alzheimer’s disease</article-title>. <source>The Lancet Neurology</source>. <volume>14</volume> (<issue>4</issue>), <fpage>388</fpage>–<lpage>405</lpage>.<pub-id pub-id-type="pmid">25792098</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <mixed-citation publication-type="journal"><name><surname>Hietala</surname><given-names>J</given-names></name>, <name><surname>Någren</surname><given-names>K</given-names></name>, <name><surname>Lehikoinen</surname><given-names>P</given-names></name>, <name><surname>Ruotsalainen</surname><given-names>U</given-names></name>, <name><surname>Syvälahti</surname><given-names>J</given-names></name>, <year>1999</year>. <article-title>Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in Vivo: A test-retest analysis</article-title>. <source>J. Cereb. Blood Flow Metab</source><volume>19</volume> (<issue>2</issue>), <fpage>210</fpage>–<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1097/00004647-199902000-00012</pub-id>.<pub-id pub-id-type="pmid">10027776</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <mixed-citation publication-type="journal"><name><surname>Hillmer</surname><given-names>AT</given-names></name>, <name><surname>Matuskey</surname><given-names>D</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Nabulsi</surname><given-names>N</given-names></name>, <name><surname>Ropchan</surname><given-names>J</given-names></name>, <name><surname>Carson</surname><given-names>RE</given-names></name>, <name><surname>O’Malley</surname><given-names>SS</given-names></name>, <name><surname>Cosgrove</surname><given-names>KP</given-names></name>, <year>2020</year>. <article-title>Tobacco smoking in people is not associated with altered 18-kDa translocator protein levels: A PET study</article-title>. <source>J. Nucl. Med</source><volume>61</volume> (<issue>8</issue>), <fpage>1200</fpage>–<lpage>1204</lpage>.<pub-id pub-id-type="pmid">32005773</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <mixed-citation publication-type="journal"><name><surname>Hodes</surname><given-names>GE</given-names></name>, <name><surname>Kana</surname><given-names>V</given-names></name>, <name><surname>Menard</surname><given-names>C</given-names></name>, <name><surname>Merad</surname><given-names>M</given-names></name>, <name><surname>Russo</surname><given-names>SJ</given-names></name>, <year>2015</year>. <article-title>Neuroimmune mechanisms of depression</article-title>. <source>Nat. Neurosci</source><volume>18</volume> (<issue>10</issue>), <fpage>1386</fpage>–<lpage>1393</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4113</pub-id>.<pub-id pub-id-type="pmid">26404713</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <mixed-citation publication-type="journal"><name><surname>Hoye</surname><given-names>J</given-names></name>, <name><surname>Toyonaga</surname><given-names>T</given-names></name>, <name><surname>Zakiniaeiz</surname><given-names>Y</given-names></name>, <name><surname>Stanley</surname><given-names>G</given-names></name>, <name><surname>Hampson</surname><given-names>M</given-names></name>, <name><surname>Morris</surname><given-names>ED</given-names></name>, <year>2022</year>. <article-title>Harmonization of [11C]raclopride brain PET images from the HR+ and HRRT: method development and validation in human subjects</article-title>. <source>EJNMMI Phys</source>. <volume>9</volume> (<issue>1</issue>).</mixed-citation>
              </ref>
              <ref id="R30">
                <mixed-citation publication-type="journal"><name><surname>Imperato</surname><given-names>A</given-names></name>, <name><surname>Puglisi-Allegra</surname><given-names>S</given-names></name>, <name><surname>Casolini</surname><given-names>P</given-names></name>, <name><surname>Zocchi</surname><given-names>A</given-names></name>, <name><surname>Angelucci</surname><given-names>L</given-names></name>, <year>1989</year>. <article-title>Stress-induced enhancement of dopamine and acetylcholine release in limbic structures: role of corticosterone</article-title>. <source>Eur. J. Pharmacol</source><volume>165</volume> (<issue>2–3</issue>), <fpage>337</fpage>–<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1016/0014-2999(89)90735-8</pub-id>.<pub-id pub-id-type="pmid">2776836</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <mixed-citation publication-type="journal"><name><surname>Joshi</surname><given-names>A</given-names></name>, <name><surname>Koeppe</surname><given-names>RA</given-names></name>, <name><surname>Fessler</surname><given-names>JA</given-names></name>, <year>2009</year>. <article-title>Reducing between scanner differences in multi-center PET studies</article-title>. <source>Neuroimage</source>. <volume>46</volume> (<issue>1</issue>), <fpage>154</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.01.057</pub-id>.<pub-id pub-id-type="pmid">19457369</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <mixed-citation publication-type="journal"><name><surname>Kelley</surname><given-names>KW</given-names></name>, <name><surname>Dantzer</surname><given-names>R</given-names></name>, <year>2011</year>. <article-title>Alcoholism and inflammation: neuroimmunology of behavioral and mood disorders</article-title>. <source>Brain Behav. Immun</source><volume>25</volume>, <fpage>S13</fpage>–<lpage>S20</lpage>.<pub-id pub-id-type="pmid">21193024</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <mixed-citation publication-type="journal"><name><surname>Koob</surname><given-names>GF</given-names></name>, <name><surname>Volkow</surname><given-names>ND</given-names></name>, <year>2010</year>. <article-title>Neurocircuitry of addiction</article-title>. <source>Neuropsychopharmacology</source><volume>35</volume> (<issue>1</issue>), <fpage>217</fpage>–<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2009.110</pub-id>.<pub-id pub-id-type="pmid">19710631</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <mixed-citation publication-type="journal"><name><surname>Lammertsma</surname><given-names>AA</given-names></name>, <name><surname>Hume</surname><given-names>SP</given-names></name>, <year>1996</year>. <article-title>Simplified reference tissue model for PET receptor studies</article-title>. <source>Neuroimage</source><volume>4</volume> (<issue>3 Pt 1</issue>), <fpage>153</fpage>–<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1006/nimg.1996.0066</pub-id>.<pub-id pub-id-type="pmid">9345505</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>D</given-names></name>, <name><surname>Slifstein</surname><given-names>M</given-names></name>, <name><surname>Broft</surname><given-names>A</given-names></name>, <name><surname>Mawlawi</surname><given-names>O</given-names></name>, <name><surname>Hwang</surname><given-names>D-R</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Cooper</surname><given-names>T</given-names></name>, <name><surname>Kegeles</surname><given-names>L</given-names></name>, <name><surname>Zarahn</surname><given-names>E</given-names></name>, <name><surname>Abi-Dargham</surname><given-names>A</given-names></name>, <name><surname>Haber</surname><given-names>SN</given-names></name>, <name><surname>Laruelle</surname><given-names>M</given-names></name>, <year>2003</year>. <article-title>Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum</article-title>. <source>J. Cereb. Blood Flow Metab</source><volume>23</volume> (<issue>3</issue>), <fpage>285</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">12621304</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <mixed-citation publication-type="journal"><name><surname>McKee</surname><given-names>SA</given-names></name>, <name><surname>Sinha</surname><given-names>R</given-names></name>, <name><surname>Weinberger</surname><given-names>AH</given-names></name>, <name><surname>Sofuoglu</surname><given-names>M</given-names></name>, <name><surname>Harrison</surname><given-names>ELR</given-names></name>, <name><surname>Lavery</surname><given-names>M</given-names></name>, <name><surname>Wanzer</surname><given-names>J</given-names></name>, <year>2011</year>. <article-title>Stress decreases the ability to resist smoking and potentiates smoking intensity and reward</article-title>. <source>J. Psychopharmacol</source><volume>25</volume> (<issue>4</issue>), <fpage>490</fpage>–<lpage>502</lpage>.<pub-id pub-id-type="pmid">20817750</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <mixed-citation publication-type="journal"><name><surname>Monterosso</surname><given-names>JR</given-names></name>, <name><surname>Aron</surname><given-names>AR</given-names></name>, <name><surname>Cordova</surname><given-names>X</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>London</surname><given-names>ED</given-names></name>, <year>2005</year>. <article-title>Deficits in response inhibition associated with chronic methamphetamine abuse</article-title>. <source>Drug Alcohol Depend</source>. <volume>79</volume> (<issue>2</issue>), <fpage>273</fpage>–<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2005.02.002</pub-id>.<pub-id pub-id-type="pmid">15967595</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <mixed-citation publication-type="journal"><name><surname>Okita</surname><given-names>K</given-names></name>, <name><surname>Petersen</surname><given-names>N</given-names></name>, <name><surname>Robertson</surname><given-names>CL</given-names></name>, <name><surname>Dean</surname><given-names>AC</given-names></name>, <name><surname>Mandelkern</surname><given-names>MA</given-names></name>, <name><surname>London</surname><given-names>ED</given-names></name>, <year>2016</year>. <article-title>Sex differences in midbrain dopamine D2-type receptor availability and association with nicotine dependence</article-title>. <source>Neuropsychopharmacology</source><volume>41</volume> (<issue>12</issue>), <fpage>2913</fpage>–<lpage>2919</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2016.105</pub-id>.<pub-id pub-id-type="pmid">27329684</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <mixed-citation publication-type="journal"><name><surname>Papademetris</surname><given-names>X</given-names></name>, <name><surname>Jackowski</surname><given-names>MP</given-names></name>, <name><surname>Rajeevan</surname><given-names>N</given-names></name>, <name><surname>DiStasio</surname><given-names>M</given-names></name>, <name><surname>Okuda</surname><given-names>H</given-names></name>, <name><surname>Constable</surname><given-names>RT</given-names></name>, <etal/>, <year>2006</year>. <article-title>BioImage suite: An integrated medical image analysis suite: an update</article-title>. <source>Insight J</source>. <volume>2006</volume>, <fpage>209</fpage>.<pub-id pub-id-type="pmid">25364771</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <mixed-citation publication-type="journal"><name><surname>Petrulli</surname><given-names>JR</given-names></name>, <name><surname>Kalish</surname><given-names>B</given-names></name>, <name><surname>Nabulsi</surname><given-names>NB</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Hannestad</surname><given-names>J</given-names></name>, <name><surname>Morris</surname><given-names>ED</given-names></name>, <year>2017</year>. <article-title>Systemic inflammation enhances stimulant-induced striatal dopamine elevation</article-title>. <source>Transl. Psychiatry</source><volume>7</volume> (<issue>3</issue>), <fpage>e1076</fpage>–<lpage>e</lpage>. <pub-id pub-id-type="doi">10.1038/tp.2017.18</pub-id>.<pub-id pub-id-type="pmid">28350401</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <mixed-citation publication-type="journal"><name><surname>Robertson</surname><given-names>CL</given-names></name>, <name><surname>Ishibashi</surname><given-names>K</given-names></name>, <name><surname>Mandelkern</surname><given-names>MA</given-names></name>, <name><surname>Brown</surname><given-names>AK</given-names></name>, <name><surname>Ghahremani</surname><given-names>DG</given-names></name>, <name><surname>Sabb</surname><given-names>F</given-names></name>, <name><surname>Bilder</surname><given-names>R</given-names></name>, <name><surname>Cannon</surname><given-names>T</given-names></name>, <name><surname>Borg</surname><given-names>J</given-names></name>, <name><surname>London</surname><given-names>ED</given-names></name>, <year>2015</year>. <article-title>Striatal D1- and D2-type dopamine receptors are linked to motor response inhibition in human subjects</article-title>. <source>J. Neurosci</source><volume>35</volume> (<issue>15</issue>), <fpage>5990</fpage>–<lpage>5997</lpage>.<pub-id pub-id-type="pmid">25878272</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <mixed-citation publication-type="journal"><name><surname>Rostène</surname><given-names>W</given-names></name>, <name><surname>Kitabgi</surname><given-names>P</given-names></name>, <name><surname>Parsadaniantz</surname><given-names>SM</given-names></name>, <year>2007</year>. <article-title>Chemokines: a new class of neuromodulator?</article-title><source>Nat. Rev. Neurosci</source><volume>8</volume> (<issue>11</issue>), <fpage>895</fpage>–<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2255</pub-id>.<pub-id pub-id-type="pmid">17948033</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <mixed-citation publication-type="journal"><name><surname>Sandiego</surname><given-names>CM</given-names></name>, <name><surname>Gallezot</surname><given-names>J-D</given-names></name>, <name><surname>Pittman</surname><given-names>B</given-names></name>, <name><surname>Nabulsi</surname><given-names>N</given-names></name>, <name><surname>Lim</surname><given-names>K</given-names></name>, <name><surname>Lin</surname><given-names>S-F</given-names></name>, <name><surname>Matuskey</surname><given-names>D</given-names></name>, <name><surname>Lee</surname><given-names>J-Y</given-names></name>, <name><surname>O’Connor</surname><given-names>KC</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Carson</surname><given-names>RE</given-names></name>, <name><surname>Hannestad</surname><given-names>J</given-names></name>, <name><surname>Cosgrove</surname><given-names>KP</given-names></name>, <year>2015</year>. <article-title>Imaging robust microglial activation after lipopolysaccharide administration in humans with PET</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>112</volume> (<issue>40</issue>), <fpage>12468</fpage>–<lpage>12473</lpage>.<pub-id pub-id-type="pmid">26385967</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <mixed-citation publication-type="journal"><name><surname>Sinha</surname><given-names>R</given-names></name>, <year>2001</year>. <article-title>How does stress increase risk of drug abuse and relapse?</article-title><source>Psychopharmacology</source><volume>158</volume> (<issue>4</issue>), <fpage>343</fpage>–<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1007/s002130100917</pub-id>.<pub-id pub-id-type="pmid">11797055</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <mixed-citation publication-type="journal"><name><surname>Sorrells</surname><given-names>SF</given-names></name>, <name><surname>Sapolsky</surname><given-names>RM</given-names></name>, <year>2007</year>. <article-title>An inflammatory review of glucocorticoid actions in the CNS</article-title>. <source>Brain Behav Immun</source>. <volume>21</volume> (<issue>3</issue>), <fpage>259</fpage>–<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2006.11.006</pub-id>.<pub-id pub-id-type="pmid">17194565</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <mixed-citation publication-type="journal"><name><surname>Tzourio-Mazoyer</surname><given-names>N</given-names></name>, <name><surname>Landeau</surname><given-names>B</given-names></name>, <name><surname>Papathanassiou</surname><given-names>D</given-names></name>, <name><surname>Crivello</surname><given-names>F</given-names></name>, <name><surname>Etard</surname><given-names>O</given-names></name>, <name><surname>Delcroix</surname><given-names>N</given-names></name>, <name><surname>Mazoyer</surname><given-names>B</given-names></name>, <name><surname>Joliot</surname><given-names>M</given-names></name>, <year>2002</year>. <article-title>Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain</article-title>. <source>Neuroimage</source><volume>15</volume> (<issue>1</issue>), <fpage>273</fpage>–<lpage>289</lpage>.<pub-id pub-id-type="pmid">11771995</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <mixed-citation publication-type="journal"><name><surname>van Velden</surname><given-names>FHP</given-names></name>, <name><surname>Mansor</surname><given-names>SM</given-names></name>, <name><surname>van Assema</surname><given-names>DME</given-names></name>, <name><surname>van Berckel</surname><given-names>BNM</given-names></name>, <name><surname>Froklage</surname><given-names>FE</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Schuit</surname><given-names>RC</given-names></name>, <name><surname>Asselin</surname><given-names>M-C</given-names></name>, <name><surname>Lammertsma</surname><given-names>AA</given-names></name>, <name><surname>Boellaard</surname><given-names>R</given-names></name>, <name><surname>Huisman</surname><given-names>MC</given-names></name>, <year>2015</year>. <article-title>Comparison of HRRT and HR+ scanners for quantitative (R)-[11C]verapamil, [11C]raclopride and [11C]flumazenil brain studies</article-title>. <source>Mol. Imag. Biol</source><volume>17</volume> (<issue>1</issue>), <fpage>129</fpage>–<lpage>139</lpage>.</mixed-citation>
              </ref>
              <ref id="R48">
                <mixed-citation publication-type="journal"><name><surname>Vezzani</surname><given-names>A</given-names></name>, <name><surname>Granata</surname><given-names>T</given-names></name>, <year>2005</year>. <article-title>Brain inflammation in epilepsy: experimental and clinical evidence</article-title>. <source>Epilepsia</source><volume>46</volume> (<issue>11</issue>), <fpage>1724</fpage>–<lpage>1743</lpage>.<pub-id pub-id-type="pmid">16302852</pub-id></mixed-citation>
              </ref>
              <ref id="R49">
                <mixed-citation publication-type="journal"><name><surname>Volkow</surname><given-names>ND</given-names></name>, <name><surname>Wang</surname><given-names>G-J</given-names></name>, <name><surname>Fowler</surname><given-names>JS</given-names></name>, <name><surname>Logan</surname><given-names>J</given-names></name>, <name><surname>Gerasimov</surname><given-names>M</given-names></name>, <name><surname>Maynard</surname><given-names>L</given-names></name>, <name><surname>Ding</surname><given-names>Y-S</given-names></name>, <name><surname>Gatley</surname><given-names>SJ</given-names></name>, <name><surname>Gifford</surname><given-names>A</given-names></name>, <name><surname>Franceschi</surname><given-names>D</given-names></name>, <year>2001</year>. <article-title>Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain</article-title>. <source>J. Neurosci</source><volume>21</volume> (<issue>2</issue>), <comment>RC121–RC.</comment></mixed-citation>
              </ref>
              <ref id="R50">
                <mixed-citation publication-type="journal"><name><surname>Volkow</surname><given-names>ND</given-names></name>, <name><surname>Wang</surname><given-names>G-J</given-names></name>, <name><surname>Fowler</surname><given-names>JS</given-names></name>, <name><surname>Logan</surname><given-names>J</given-names></name>, <name><surname>Franceschi</surname><given-names>D</given-names></name>, <name><surname>Maynard</surname><given-names>L</given-names></name>, <name><surname>Ding</surname><given-names>Y-S</given-names></name>, <name><surname>Gatley</surname><given-names>SJ</given-names></name>, <name><surname>Gifford</surname><given-names>A</given-names></name>, <name><surname>Zhu</surname><given-names>W</given-names></name>, <name><surname>Swanson</surname><given-names>JM</given-names></name>, <year>2002</year>. <article-title>Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications</article-title>. <source>Synapse</source><volume>43</volume> (<issue>3</issue>), <fpage>181</fpage>–<lpage>187</lpage>.<pub-id pub-id-type="pmid">11793423</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <mixed-citation publication-type="journal"><name><surname>Volkow</surname><given-names>ND</given-names></name>, <name><surname>Tomasi</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>G-J</given-names></name>, <name><surname>Telang</surname><given-names>F</given-names></name>, <name><surname>Fowler</surname><given-names>JS</given-names></name>, <name><surname>Logan</surname><given-names>J</given-names></name>, <name><surname>Benveniste</surname><given-names>H</given-names></name>, <name><surname>Kim</surname><given-names>R</given-names></name>, <name><surname>Thanos</surname><given-names>PK</given-names></name>, <name><surname>Ferre</surname><given-names>S</given-names></name>, <year>2012</year>. <article-title>Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain</article-title>. <source>J. Neurosci</source><volume>32</volume> (<issue>19</issue>), <fpage>6711</fpage>–<lpage>6717</lpage>.<pub-id pub-id-type="pmid">22573693</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <mixed-citation publication-type="journal"><name><surname>Wand</surname><given-names>GS</given-names></name>, <name><surname>Oswald</surname><given-names>LM</given-names></name>, <name><surname>McCaul</surname><given-names>ME</given-names></name>, <name><surname>Wong</surname><given-names>DF</given-names></name>, <name><surname>Johnson</surname><given-names>E</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Kuwabara</surname><given-names>H</given-names></name>, <name><surname>Kumar</surname><given-names>A</given-names></name>, <year>2007</year>. <article-title>Association of amphetamine-induced striatal dopamine release and cortisol responses to psychological stress</article-title>. <source>Neuropsychopharmacology</source><volume>32</volume> (<issue>11</issue>), <fpage>2310</fpage>–<lpage>2320</lpage>.<pub-id pub-id-type="pmid">17342167</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <mixed-citation publication-type="journal"><name><surname>Whitton</surname><given-names>AE</given-names></name>, <name><surname>Reinen</surname><given-names>JM</given-names></name>, <name><surname>Slifstein</surname><given-names>M</given-names></name>, <name><surname>Ang</surname><given-names>Y-S</given-names></name>, <name><surname>McGrath</surname><given-names>PJ</given-names></name>, <name><surname>Iosifescu</surname><given-names>DV</given-names></name>, <name><surname>Abi-Dargham</surname><given-names>A</given-names></name>, <name><surname>Pizzagalli</surname><given-names>DA</given-names></name>, <name><surname>Schneier</surname><given-names>FR</given-names></name>, <year>2020</year>. <article-title>Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression</article-title>. <source>Brain</source><volume>143</volume> (<issue>2</issue>), <fpage>701</fpage>–<lpage>710</lpage>.<pub-id pub-id-type="pmid">32040562</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <mixed-citation publication-type="journal"><name><surname>Woodcock</surname><given-names>EA</given-names></name>, <name><surname>Hillmer</surname><given-names>AT</given-names></name>, <name><surname>Sandiego</surname><given-names>CM</given-names></name>, <name><surname>Maruff</surname><given-names>P</given-names></name>, <name><surname>Carson</surname><given-names>RE</given-names></name>, <name><surname>Cosgrove</surname><given-names>KP</given-names></name>, <name><surname>Pietrzak</surname><given-names>RH</given-names></name>, <year>2021</year>. <article-title>Acute neuroimmune stimulation impairs verbal memory in adults: A PET brain imaging study</article-title>. <source>Brain Behav. Immun</source><volume>91</volume>, <fpage>784</fpage>–<lpage>787</lpage>.<pub-id pub-id-type="pmid">33002632</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <mixed-citation publication-type="journal"><name><surname>Zakiniaeiz</surname><given-names>Y</given-names></name>, <name><surname>Hillmer</surname><given-names>AT</given-names></name>, <name><surname>Matuskey</surname><given-names>D</given-names></name>, <name><surname>Nabulsi</surname><given-names>N</given-names></name>, <name><surname>Ropchan</surname><given-names>J</given-names></name>, <name><surname>Mazure</surname><given-names>CM</given-names></name>, <name><surname>Picciotto</surname><given-names>MR</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>McKee</surname><given-names>SA</given-names></name>, <name><surname>Morris</surname><given-names>ED</given-names></name>, <name><surname>Cosgrove</surname><given-names>KP</given-names></name>, <year>2019</year>. <article-title>Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers</article-title>. <source>NPP</source><volume>44</volume> (<issue>13</issue>), <fpage>2205</fpage>–<lpage>2211</lpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Fig. 1.</label>
              <caption>
                <p id="P47">Study Design: The blue boxes refer to the protocol for all the smokers in Study 1. Grey (marked with asterisks (*) and blue boxes combined, represent the protocol for healthy controls, included in Study 2.</p>
              </caption>
              <graphic xlink:href="nihms-1888802-f0001" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Fig. 2.</label>
              <caption>
                <p id="P48">Smokers ΔBP<sub>ND</sub> values comparison for MP + PBO and MP + LPS conditions. Smokers showed significantly higher ΔBP<sub>ND</sub> values under the MP + LPS condition compared to the MP + PBO, <italic toggle="yes">p &lt;</italic> 0.001.</p>
              </caption>
              <graphic xlink:href="nihms-1888802-f0002" position="float"/>
            </fig>
            <fig position="float" id="F3">
              <label>Fig. 3.</label>
              <caption>
                <p id="P49">Smoker and healthy control (combined sample) ΔBP<sub>ND</sub> values comparison for MP + PBO and MP + LPS conditions. Subjects showed significantly higher ΔBP<sub>ND</sub> values under the MP + LPS condition compared to the MP + PBO, <italic toggle="yes">p &lt;</italic> 0.001. Smokers are shown in open squares and healthy controls are shown in closed circles.</p>
              </caption>
              <graphic xlink:href="nihms-1888802-f0003" position="float"/>
            </fig>
            <table-wrap position="float" id="T1">
              <label>Table 1</label>
              <caption>
                <p id="P50">Subject demographics. Smokers and healthy controls were well-matched on demographics, drug dosing, and scanning parameters.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="left" valign="top" rowspan="1" colspan="1">Study 1: Smokers (N = 8)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Study 2: Healthy Controls (N = 8)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Smokers v. Healthy Controls <italic toggle="yes">p</italic>-value</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Sex (N female)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.64</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Age</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">33 ± 4.0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">31 ± 3.9</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.79</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Cigarettes/day</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">15 ± 2.9</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Years smoked</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">16 ± 4.2</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">FTND</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.8 ± 0.8</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Scan Order (N PBO first)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.30</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Bodyweight (kg)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">75 ± 6.0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">69 ± 4.7</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.42</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">LPS dose (ng)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">60 ± 4.7</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">55 ± 3.7</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">LPS dose/bodyweight (ng/kg)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.80 ± 0.0006</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.80 ± 0.003</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.25</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">MP/bodyweight (mg/kg)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.56 ± 0.04</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.60 ± 0.05</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.48</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Injected Activity (mCi)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">19 ± 0.61</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">17.4 ± 0.61</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.15</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">ΔInjected Mass (PBO-Baseline; μg)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.34 ± 0.88</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.20 ± 0.08</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.87</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">ΔInjected Mass (LPS-Baseline; μg)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.05 ± 0.57</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.10 ± 0.09</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.94</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <p id="P51">ΔInjected Mass refers to the difference in the mass of the radiotracer injected between the conditions described. FTND = Fagerström Test for Nicotine Dependence. Mean ± SE shown.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
